Key result
4'-thioIDU and other thymidine analogs show preclinical antiviral activity against orthopoxviruses with human therapeutic potential.
Pyrimidine analogs, particularly 4'-thioIDU, demonstrate promising antiviral activity against orthopoxviruses in preclinical models.
Answers are grounded in this paper and cite their sources.
May support clinical trials of 4'-thioIDU for orthopoxviruses; leaves human efficacy open pending prospective studies.
The search for effective therapies for orthopoxvirus infections has identified diverse classes of molecules with antiviral activity. Pyrimidine analogs, such as 5-iodo-2'-deoxyuridine (idoxuridine, IDU) were among the first compounds identified with antiviral activity against a number of orthopoxviruses and have been reported to be active both in vitro and in animal models of infection. More recently, additional analogs have been reported to have improved antiviral activity against orthopoxviruses including several derivatives of deoxyuridine with large substituents in the 5 position, as well as analogs with modifications in the deoxyribose moiety including (north)-methanocarbathymidine, and 5-iodo-4'-thio-2'-deoxyuridine (4'-thioIDU). The latter molecule has proven to have good antiviral activity against the orthopoxviruses both in vitro and in vivo and has the potential to be an effective therapy in humans.
No takes yet. Share an insight, caveat, or question.
Prichard et al. (2010) conducted a review in Orthopoxvirus infections. 4'-thioIDU and Thymidine Analogs was evaluated on Antiviral activity. 4'-thioIDU and other thymidine analogs demonstrate good antiviral activity against orthopoxviruses in vitro and in vivo, showing potential as effective therapies in humans.
Synapse has enriched 10 related papers. Consider them for comparative context: